Healthcare Pipeline Stocks Gain Ground: EBR Systems (ASX:EBR), Recce (ASX:RCE) and Ceretas (ASX:CTS)

Sonal Goyal

30 October 2026 11:54 AM AEDT

Healthcare Pipeline Stocks Gain Ground: EBR Systems (ASX:EBR), Recce (ASX:RCE) and Ceretas (ASX:CTS)

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

EBR Systems (ASX:EBR) traded at $0.130, up 8.33%, Recce (ASX:RCE) at $0.360, up 9.09%, and Ceretas (ASX:CTS) at $0.975, up 8.33%, during the 30 October 2026 session.
Ceretas released its Quarterly Report on the same day as its share move, while EBR and Recce announced updates on 20 and 22 October 2026.
Each company is at an early or pre-commercial stage in its regulatory or clinical program.

Three ASX-listed healthcare companies with products in regulatory review or clinical development traded higher during the Trading session on 30 October 2026. EBR Systems Inc (ASX:EBR) traded at $0.130, up 8.33%, Recce Pharmaceuticals Ltd (ASX:RCE) at $0.360, up 9.09%, and Ceretas Ltd (ASX:CTS) at $0.975, up 8.33%. The S&P/ASX 200 (ASX:XJO) was at 8,973.00, up 0.91% or 81.20 points at 11:15 am. Their updates cover a Therapeutic Goods Administration submission, a commercial licence and a first trial enrolment, and each is summarised below.

EBR Systems (ASX:EBR): TGA Submission (20 October 2026)

EBR submitted its application to the Therapeutic Goods Administration for inclusion of the WiSE System on the Australian Register of Therapeutic Goods. The submission is expected to be assessed under a Priority Review Determination granted in April 2026. The company says the timing and outcome cannot be guaranteed.

Recce (ASX:RCE): Arrotex Licence (22 October 2026)

Recce entered into an exclusive licence and commercialisation agreement with Arrotex Pharmaceuticals for R327G in Australia and New Zealand. No upfront or milestone payments were made, and Recce will receive a profit share of gross Margin from sales while remaining the manufacturer and supplier.

Ceretas (ASX:CTS): CERE-CALM Enrolment (30 October 2026)

Ceretas enrolled its first patient in the Phase 2 CERE-CALM trial shortly after quarter end and completed Milestone 3 of its CUREator+ grant, triggering a $692,578 tranche. Cash was $7.1 million at 30 September 2026. The quarterly report was released on the same day as the share move.

Sector Context

Medical device and drug developers depend on regulatory approvals, clinical evidence and commercial partners. Regulatory pathways differ between jurisdictions, and each company in this group is working through a different stage, from an overseas-approved device seeking Australian listing to a Phase 3 candidate and an early-stage clinical trial.

Risks

Regulatory and clinical outcomes are uncertain, and none of the three products is approved for commercial sale in Australia. Recce's profit share depends on Arrotex's sales. Ceretas's trial has only just begun recruitment, and its cash position will decline with operating costs. EBR's device is available commercially only in the United States.

What Lies Ahead

EBR expects to work with the TGA through the Priority Review process. Recce's Phase 3 program will continue. Ceretas expects recruitment at its additional sites to begin and plans further work on its next-generation device by mid-CY2027.

The Bottom Line

EBR, Recce and Ceretas each reported regulatory or clinical progress in recent weeks, and their shares traded higher during the 30 October 2026 session. The outcomes of the TGA review, the Phase 3 program and the CERE-CALM trial will shape each company's position in the coming periods.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.